Gw Pharmaceuticals Plc Ads (GWPH) 78.09 $GWPH
Peak Pharmaceuticals Brings CBD-based Therapies to Pets
ACCESSWIRE - Wed Feb 11, 8:41AM CST
WHITEFISH, MT / ACCESSWIRE / February 11, 2015 / The medical marijuana industry has grown at a 16.2% CAGR between 2009 and 2014 to reach $2 billion in revenue, according to IBISWorld, driven by widespread legalization and promising new data from clinical trials. Some of the non-psychoactive cannabinoids found within the drug - including cannabidiol("CBD"
- could prove useful in treating conditions ranging from neurological diseases like Alzheimer's disease to metabolic diseases like diabetes or obesity.
ZTS: 45.46 (-0.33), GWPH: 78.09 (+1.70), PETM: 82.70 (+0.03)
5 Diseases You Never Knew Marijuana Could Fight or Potentially Cure
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 08, 10:41AM CST
Source: Flickr user Matthew Kenwrick. To say there's been a dramatic shift in sentiment toward marijuana over the past decade is an understatement. In just one decade, the American public went from opposing the legalization of marijuana by a...
GWPH: 78.09 (+1.70)
After Marijuana Flops in Cancer Pain, Investors Look to the Future
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 11:59AM CST
Source: Flickr user Matthew Kenwrick . For more than 15 years, GW Pharmaceuticals has been researching marijuana cannabinoids (e.g. THC and CBD) in a bid to profit from pot. The company already has the THC-derived Sativex on the market in...
GWPH: 78.09 (+1.70)
Buzzkill: Marijuana Stock Frenzy Looks Like It's Totally Crashed
at The Street - Sat Feb 07, 6:00AM CST
Pot-related stocks have gone up in flames over the past year amid legal woes and failure to show any profits.
GWPH: 78.09 (+1.70), H: 59.51 (-0.14)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
GW Pharmaceuticals to Present at the Leerink 2015 Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 6:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group" , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Leerink 2015 Global Healthcare Conference to be held at the Waldorf Astoria Hotel in New York City on Wednesday, 11 February, 2015 at 3:30 p.m. EST.
GWPH: 78.09 (+1.70)
GW Pharmaceuticals' (GWPH) CEO Justin Gover on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 04, 11:48AM CST
GWPH: 78.09 (+1.70)
Earth Science Tech Building A Nutrition Empire Based On High Grade CBD and Nutraceutical Retailing
ACCESSWIRE - Wed Feb 04, 8:11AM CST
WHITEFISH, MT / ACCESSWIRE / February 4, 2015 / Earth Science Tech (OTC: ETST) has been making excellent progress validating the efficacy of their proprietary CBD (cannabidiol) Rich Hemp Oil product lately via work done at the University of Central Oklahoma, carried out under the visionary eye of the university's Assistant Dean of the College of Mathematics & Science, world-renown scientist and researcher Dr. Wei R. Chen. Following up on initial preliminary testing in animal breast cancer last year, which showed that the appropriate dosages could indeed inhibit cancer cell proliferation at a significant rate, subsequent research into the product's ability to bolster the body's immune system by stimulating the production of a key cytokine (TNF-alpha, a signaling protein) in macrophages ("big eater" white blood cells that engulf and digest things like microbes and cancer cells), has now produced promising results as well.
HLF: 32.78 (-0.84), CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), NATR: 14.18 (-0.04), GWPH: 78.09 (+1.70)
GW Pharmaceuticals (GWPH) Posts Narrower Q1 Loss (Revised) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:44AM CST
GW Pharmaceuticals (GWPH) Posts Narrower Q1 Loss (Revised)
GWPH: 78.09 (+1.70)
GW Pharma ups revenues 7% in FQ1
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 7:16AM CST
GWPH: 78.09 (+1.70)
GW Pharmaceuticals EPS of -$0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 6:28AM CST
GWPH: 78.09 (+1.70)
GW Pharmaceuticals plc Reports First Quarter 2015 Financial Results and Operational Progress
GlobeNewswire - Wed Feb 04, 6:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the first quarter ended 31 December 2014.
GWPH: 78.09 (+1.70)
Notable earnings before Wednesday's open
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:30PM CST
TMHC: 18.96 (-0.09), CLX: 109.00 (+0.74), MPLX: 77.64 (-0.37), SNE: 27.30 (+0.19), MOD: 12.68 (+0.10), RL: 135.20 (-0.60), HUM: 152.67 (-1.06), BSX: 14.98 (+0.24), MSI: 69.91 (-0.09), WHR: 213.23 (+0.18), GWPH: 78.09 (+1.70), CKSW: 8.08 (-0.01), EVR: 52.14 (+0.07), SE: 36.81 (+0.61), LFUS: 98.58 (+0.50), SMG: 66.37 (-0.90), SO: 45.88 (-0.68), HAIN: 59.48 (+0.45), LVLT: 53.49 (-0.52), ADP: 88.75 (+1.00), STE: 65.50 (-0.35), ARCB: 39.76 (+0.55), ABG: 79.87 (-0.49), MPC: 103.48 (+2.08), MRK: 58.81 (-0.07), SLAB: 49.26 (-0.27), NJR: 63.54 (-1.32), GM: 37.62 (-0.40), CTSH: 60.23 (-0.05), LG: 51.59 (-0.47)
Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 1:40PM CST
GW Pharmaceuticals (GWPH), which is scheduled to report first-quarter fiscal 2015 results on Feb 4, had delivered a positive earnings surprise of 104.35% in the last quarter.
ACT: 285.37 (+3.71), GWPH: 78.09 (+1.70), ARIA: 7.35 (+0.45), REGN: 402.40 (+0.66)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03), ICN: 21.26 (-0.05)
Stay Away From Financials - Cramer's Lightning Round (1/30/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Feb 02, 4:37AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, January 30. Bullish Calls: FireEye (NASDAQ: FEYE ): " I like FireEye, I like the whole segment." Vector Group (NYSE: VGR ): " I like...
WFM: 56.15 (-0.15), HAIN: 59.48 (+0.45), FEYE: 42.26 (+2.63), SWKS: 81.85 (-0.57), ALLY: 22.05 (+0.21), GWPH: 78.09 (+1.70), AON: 100.56 (-0.18), STKL: 11.59 (-0.07), RMTI: 11.17 (+0.15), SIMO: 29.08 (-0.39), VGR: 22.52 (-0.26)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
'Mad Money' Lightning Round: I'm in GW Pharmaceuticals for the Long Term
at The Street - Sat Jan 31, 5:00AM CST
Cramer likes FireEye, does not like Rockwell Medical and is staying away from Ally Financial and Aon.
WFM: 56.15 (-0.15), HAIN: 59.48 (+0.45), FEYE: 42.26 (+2.63), SWKS: 81.85 (-0.57), GWPH: 78.09 (+1.70), ALLY: 22.05 (+0.21), STKL: 11.59 (-0.07), AON: 100.56 (-0.18), RMTI: 11.17 (+0.15), SIMO: 29.08 (-0.39), VGR: 22.52 (-0.26)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jan 30, 7:14PM CST
Cramer will be watching earnings from Exxon Mobil, General Motors and Buffalo Wild Wings, among many others.
WFM: 56.15 (-0.15), SHAK: 40.69 (+0.04), FEYE: 42.26 (+2.63), SWKS: 81.85 (-0.57), CLX: 109.00 (+0.74), ALLY: 22.05 (+0.21), XOM: 93.37 (+1.00), DIS: 104.17 (+0.59), STKL: 11.59 (-0.07), AON: 100.56 (-0.18), RMTI: 11.17 (+0.15), BWLD: 187.27 (+0.30), NOV: 53.36 (+0.80), HAIN: 59.48 (+0.45), GWPH: 78.09 (+1.70), BOOT: 23.04 (-0.52), CMG: 674.89 (+4.60), GM: 37.62 (-0.40), BP: 41.93 (+0.59), GOOGL: 551.16 (+5.15), TWTR: 48.50 (+0.55), SIMO: 29.08 (-0.39), VGR: 22.52 (-0.26), APC: 89.44 (+2.13)
Peak Pharmaceuticals Brings CBD-based Therapies to Pets
ACCESSWIRE - Wed Feb 11, 8:41AM CST
WHITEFISH, MT / ACCESSWIRE / February 11, 2015 / The medical marijuana industry has grown at a 16.2% CAGR between 2009 and 2014 to reach $2 billion in revenue, according to IBISWorld, driven by widespread legalization and promising new data from clinical trials. Some of the non-psychoactive cannabinoids found within the drug - including cannabidiol("CBD"
- could prove useful in treating conditions ranging from neurological diseases like Alzheimer's disease to metabolic diseases like diabetes or obesity. ZTS: 45.46 (-0.33), GWPH: 78.09 (+1.70), PETM: 82.70 (+0.03)
5 Diseases You Never Knew Marijuana Could Fight or Potentially Cure
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 08, 10:41AM CST
Source: Flickr user Matthew Kenwrick. To say there's been a dramatic shift in sentiment toward marijuana over the past decade is an understatement. In just one decade, the American public went from opposing the legalization of marijuana by a...
GWPH: 78.09 (+1.70)
After Marijuana Flops in Cancer Pain, Investors Look to the Future
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 11:59AM CST
Source: Flickr user Matthew Kenwrick . For more than 15 years, GW Pharmaceuticals has been researching marijuana cannabinoids (e.g. THC and CBD) in a bid to profit from pot. The company already has the THC-derived Sativex on the market in...
GWPH: 78.09 (+1.70)
Buzzkill: Marijuana Stock Frenzy Looks Like It's Totally Crashed
at The Street - Sat Feb 07, 6:00AM CST
Pot-related stocks have gone up in flames over the past year amid legal woes and failure to show any profits.
GWPH: 78.09 (+1.70), H: 59.51 (-0.14)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
GW Pharmaceuticals to Present at the Leerink 2015 Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 6:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Leerink 2015 Global Healthcare Conference to be held at the Waldorf Astoria Hotel in New York City on Wednesday, 11 February, 2015 at 3:30 p.m. EST. GWPH: 78.09 (+1.70)
GW Pharmaceuticals' (GWPH) CEO Justin Gover on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 04, 11:48AM CST
GWPH: 78.09 (+1.70)
Earth Science Tech Building A Nutrition Empire Based On High Grade CBD and Nutraceutical Retailing
ACCESSWIRE - Wed Feb 04, 8:11AM CST
WHITEFISH, MT / ACCESSWIRE / February 4, 2015 / Earth Science Tech (OTC: ETST) has been making excellent progress validating the efficacy of their proprietary CBD (cannabidiol) Rich Hemp Oil product lately via work done at the University of Central Oklahoma, carried out under the visionary eye of the university's Assistant Dean of the College of Mathematics & Science, world-renown scientist and researcher Dr. Wei R. Chen. Following up on initial preliminary testing in animal breast cancer last year, which showed that the appropriate dosages could indeed inhibit cancer cell proliferation at a significant rate, subsequent research into the product's ability to bolster the body's immune system by stimulating the production of a key cytokine (TNF-alpha, a signaling protein) in macrophages ("big eater" white blood cells that engulf and digest things like microbes and cancer cells), has now produced promising results as well.
HLF: 32.78 (-0.84), CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), NATR: 14.18 (-0.04), GWPH: 78.09 (+1.70)
GW Pharmaceuticals (GWPH) Posts Narrower Q1 Loss (Revised) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:44AM CST
GW Pharmaceuticals (GWPH) Posts Narrower Q1 Loss (Revised)
GWPH: 78.09 (+1.70)
GW Pharma ups revenues 7% in FQ1
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 7:16AM CST
GWPH: 78.09 (+1.70)
GW Pharmaceuticals EPS of -$0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 6:28AM CST
GWPH: 78.09 (+1.70)
GW Pharmaceuticals plc Reports First Quarter 2015 Financial Results and Operational Progress
GlobeNewswire - Wed Feb 04, 6:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the first quarter ended 31 December 2014.
GWPH: 78.09 (+1.70)
Notable earnings before Wednesday's open
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:30PM CST
TMHC: 18.96 (-0.09), CLX: 109.00 (+0.74), MPLX: 77.64 (-0.37), SNE: 27.30 (+0.19), MOD: 12.68 (+0.10), RL: 135.20 (-0.60), HUM: 152.67 (-1.06), BSX: 14.98 (+0.24), MSI: 69.91 (-0.09), WHR: 213.23 (+0.18), GWPH: 78.09 (+1.70), CKSW: 8.08 (-0.01), EVR: 52.14 (+0.07), SE: 36.81 (+0.61), LFUS: 98.58 (+0.50), SMG: 66.37 (-0.90), SO: 45.88 (-0.68), HAIN: 59.48 (+0.45), LVLT: 53.49 (-0.52), ADP: 88.75 (+1.00), STE: 65.50 (-0.35), ARCB: 39.76 (+0.55), ABG: 79.87 (-0.49), MPC: 103.48 (+2.08), MRK: 58.81 (-0.07), SLAB: 49.26 (-0.27), NJR: 63.54 (-1.32), GM: 37.62 (-0.40), CTSH: 60.23 (-0.05), LG: 51.59 (-0.47)
Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 1:40PM CST
GW Pharmaceuticals (GWPH), which is scheduled to report first-quarter fiscal 2015 results on Feb 4, had delivered a positive earnings surprise of 104.35% in the last quarter.
ACT: 285.37 (+3.71), GWPH: 78.09 (+1.70), ARIA: 7.35 (+0.45), REGN: 402.40 (+0.66)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03), ICN: 21.26 (-0.05)
Stay Away From Financials - Cramer's Lightning Round (1/30/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Feb 02, 4:37AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, January 30. Bullish Calls: FireEye (NASDAQ: FEYE ): " I like FireEye, I like the whole segment." Vector Group (NYSE: VGR ): " I like...
WFM: 56.15 (-0.15), HAIN: 59.48 (+0.45), FEYE: 42.26 (+2.63), SWKS: 81.85 (-0.57), ALLY: 22.05 (+0.21), GWPH: 78.09 (+1.70), AON: 100.56 (-0.18), STKL: 11.59 (-0.07), RMTI: 11.17 (+0.15), SIMO: 29.08 (-0.39), VGR: 22.52 (-0.26)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
'Mad Money' Lightning Round: I'm in GW Pharmaceuticals for the Long Term
at The Street - Sat Jan 31, 5:00AM CST
Cramer likes FireEye, does not like Rockwell Medical and is staying away from Ally Financial and Aon.
WFM: 56.15 (-0.15), HAIN: 59.48 (+0.45), FEYE: 42.26 (+2.63), SWKS: 81.85 (-0.57), GWPH: 78.09 (+1.70), ALLY: 22.05 (+0.21), STKL: 11.59 (-0.07), AON: 100.56 (-0.18), RMTI: 11.17 (+0.15), SIMO: 29.08 (-0.39), VGR: 22.52 (-0.26)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jan 30, 7:14PM CST
Cramer will be watching earnings from Exxon Mobil, General Motors and Buffalo Wild Wings, among many others.
WFM: 56.15 (-0.15), SHAK: 40.69 (+0.04), FEYE: 42.26 (+2.63), SWKS: 81.85 (-0.57), CLX: 109.00 (+0.74), ALLY: 22.05 (+0.21), XOM: 93.37 (+1.00), DIS: 104.17 (+0.59), STKL: 11.59 (-0.07), AON: 100.56 (-0.18), RMTI: 11.17 (+0.15), BWLD: 187.27 (+0.30), NOV: 53.36 (+0.80), HAIN: 59.48 (+0.45), GWPH: 78.09 (+1.70), BOOT: 23.04 (-0.52), CMG: 674.89 (+4.60), GM: 37.62 (-0.40), BP: 41.93 (+0.59), GOOGL: 551.16 (+5.15), TWTR: 48.50 (+0.55), SIMO: 29.08 (-0.39), VGR: 22.52 (-0.26), APC: 89.44 (+2.13)
